Chidamide in Patients With Relapsed or Refractory Peripheral T-cell Lymphoma (R/R PTCL)

This study is testing a drug called chidamide — a type of medication that affects how cancer genes are switched on or off — in patients with relapsed or refractory peripheral T-cell lymphoma (a type of blood cancer that has come back or stopped responding to treatment). The goal is to find out how effective and safe chidamide is for this difficult-to-treat cancer. **You may be eligible if...** - You are between 20 and 75 years old - You have been diagnosed with one of several types of T-cell lymphoma confirmed by biopsy - Your lymphoma has relapsed or is no longer responding to at least one prior treatment - Your general health is good enough to participate (ECOG score 0–1) - You have at least one measurable tumor site **You may NOT be eligible if...** - You have received a similar type of drug called an HDAC inhibitor before - You are pregnant or breastfeeding - Your lymphoma has spread to the brain - You have a history of serious heart rhythm problems or heart failure Talk to your doctor to see if this trial is right for you.